Latest End point of clinical trials Stories
SAN DIEGO, June 3, 2014 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and
In a head-to-head comparison of two Food and Drug Administration-approved drugs for the treatment of relapsed chronic lymphocytic leukemia (CLL), ibrutinib significantly outperformed ofatumumab as a second-line therapy.
Pre-specified MGMT and HLA Subgroup Analyses Show Potentially Clinically Meaningful Survival Advantages for ICT-107 Treated Patients LOS ANGELES, June 1, 2014 /PRNewswire/ -- ImmunoCellular
Data Support Adoption of Stable Disease as Response Criterion, Raise Intriguing Hypotheses about Sequential Therapy and Utility of IL-2 as Salvage Option CHICAGO, May 31, 2014 /PRNewswire/
Latest Data Sweep from Large Subgroup of Patients Shows a Strong 50% Improvement in Overall Survival for ThermoDox® LAWRENCEVILLE, N.J., April 24, 2014 /PRNewswire/ -- Celsion Corporation
Professor Riccardo Lencioni is giving an honorary lecture on April 24, 2014 which will highlight the latest findings and lessons learned from the HEAT Study and the design of the Phase III OPTIMA Study LAWRENCEVILLE,
Conference call to be held on Tuesday, March 11, 2014 at 4:30 p.m. Eastern Time BOTHELL, Wash.
An Italian study of more than 1,300 patients finds those with good prognostic factors fair about the same, regardless of their treatment. Raleigh, NC (PRWEB)
Latest Data from Large Subgroup of Patients Shows that the Combination of ThermoDox® and Optimized RFA Provides a Statistically Significant Survival Improvement of Over 50% LAWRENCEVILLE,
Topline Data Will Be Presented at Biotech Showcase HEIDELBERG, Germany, Jan.
- A poem in which the author retracts something said in an earlier poem.